deoxycytidine

Deoxycytidine is a naturally occurring pyrimidine nucleoside being investigated by Virginia Commonwealth University as a chemoprotectant for use in combination with high-dose cytarabine (Ara-C) therapy. It serves as a substrate for deoxycytidine kinase (dCK), the enzyme responsible for the initial phosphorylation and activation of cytarabine. By competing with cytarabine for dCK, deoxycytidine is intended to modulate the metabolism and reduce the systemic toxicity of high-dose cytarabine, potentially protecting normal tissues while maintaining the drug's anti-leukemic efficacy. It has been evaluated in Phase I clinical trials for the treatment of various hematologic malignancies, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), lymphoma, and multiple myeloma.

Other names

2'-deoxycytidinedCdeoxycytosine